The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: An immunohistochemical analysis

Acta Orthopaedica et Traumatologica Turcica

Volumn 43, Issue 1, 2009, Pages 28-34

  Ozger, Harzem ^b   Eralp, Levent ^b   Atalar, Ata Can ^b   Toker, Berkin ^b   Esberk Ates, Lora ^a   Sungur, Mustafa ^b   Bilgic, Bilge ^b   Ayan, Inci ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biological; Drug resistance; Immunohistochemistry; Neoplasm; Neoplasm proteins; Osteosarcoma; Prognosis; Survival analysis; Tumor markers; Tumor suppressor protein p53

Indexed keywords

GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; PROTEIN P53; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CHILD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; PROGNOSIS; TIME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HSP27 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOSARCOMA; P-GLYCOPROTEINS; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67650137057     PISSN: 1017995X     EISSN: None     Source Type: Journal    
DOI: 10.3944/AOTT.2009.028     Document Type: Article

References (26)

1. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-85.
2. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
3. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
4. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122:559-65.
5. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001;33:11-7.
6. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993;68:1134-9.
7. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994;69:743-8.
8. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 2000;82:85-7.
9. Serra M, Maurici D, Scotlandi K, Barbanti-Brodano G, Manara MC, Benini S, et al. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol 1999;14:301-7.
10. Serra M, Scotlandi K, Manara MC, Maurici D, Benini S, Sarti M, et al. Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 1995;31A:1998-2002.
11. MacDonald NJ, de la Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995;31A:1096-100.
12. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 2000;31:709-16.
13. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, et al. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 1993;119:172-8.
14. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997;79:2336-44.
15. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27.
16. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90.
17. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-8.
18. Özger H, Eralp L, Atalar AC, Toker B, Ayan I, Kebudi R, et al. Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma. [Article in Turkish] Acta Orthop Traumatol Turc 2007;41:211-9.
19. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006; 24:1161-8.
20. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-24.
21. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg [Am] 2002;84:49-57.
22. Pápai Z, Féja CN, Hanna EN, Sztán M, Oláh E, Szendrôi M. P53 Overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res 1997;3:15-9.
23. Honoki K, Tsutsumi M, Miyauchi Y, Mii Y, Tsujiuchi T, Morishita T, et al. Increased expression of nucleoside diphosphate kinase/nm23 and c-Ha-ras mRNA is associated with spontaneous lung metastasis in rat-transplantable osteosarcomas. Cancer Res 1993;53:5038-42.
24. Schneider J, Jimenez E, Marenbach K, Marx D, Meden H. Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 1998;18:2967-71.
25. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 2000;196:665-73.
26. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997;89:1706-15.